Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC

Status Recruiting

Clinical Trial Summary

Patient with multiple metastases, not eligible for surgery, might not profit from intensive chemotherapy regimens. Therefore less intensive regimens focusing on survival and disease control may be a better choice for first line treatment. Therefore this study investigates the combination of capecitabine and bevacizumab versus the combination of capecitabine, bevacizumab and irinotecan. In case of progressive disease, the therapy in patients treated with capecitabine and bevacizumab is intensified by adding irinotecan. Primary endpoint is time-of-failure strategy (TFS) comparing both treatment arms.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01249638
Study type	Interventional
Source	Ludwig-Maximilians - University of Munich
Contact	Volker Heinemann, Prof. Dr.
Phone	+49 89 7095 0
Email	volker.heinemann@med.uni-muenchen.de
Status	Recruiting
Phase	Phase 3
Start date	December 2010
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03941080` - Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
Completed	`NCT03213314` - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies	N/A
Completed	`NCT03647839` - Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer	Phase 2
Recruiting	`NCT05057052` - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis	Phase 2
Terminated	`NCT02316496` - Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study	Phase 2
Completed	`NCT03251612` - Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer	Phase 2
Completed	`NCT02380443` - AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT02149784` - Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients	Phase 3
Recruiting	`NCT01959061` - Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases	Phase 4
Terminated	`NCT01668680` - Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma	Phase 2
Recruiting	`NCT05068531` - Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
Not yet recruiting	`NCT04525807` - Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
Completed	`NCT04482608` - The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Recruiting	`NCT03193710` - The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved	N/A
Recruiting	`NCT04854213` - PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)	N/A
Suspended	`NCT04108481` - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer	Phase 1/Phase 2
Completed	`NCT03142516` - FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status	Phase 2
Completed	`NCT03144804` - A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer	Phase 2
Active, not recruiting	`NCT01910610` - Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer	Phase 3
Recruiting	`NCT05759728` - A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer	Phase 1/Phase 2